Gleevec receives US approval as first treatment to reduce risk of cancer returning in patients with gastrointestinal stromal tum

January 13, 2009

GIST, a life-threatening cancer, recurs in as many as one of two patients; recurrent tumors are often more aggressive than primary tumors